☆ 4.7 Editorial Material

CRISPR-Edited Immune Effectors: The End of the Beginning

MOLECULAR THERAPY (2020)

Get Full Text
Add to Collection

Journal

MOLECULAR THERAPY
Volume 28, Issue 4, Pages 995-996

Publisher

CELL PRESS
DOI: 10.1016/j.ymthe.2020.03.009

Keywords

-

Categories

Biotechnology & Applied Microbiology Genetics & Heredity Medicine, Research & Experimental

Funding

  1. National Cancer Institute [P50CA126752]
  2. SU2C/AACR Meg Vosburg T cell Lymphoma Dream Team, [604817]
  3. Leukemia and Lymphoma Society

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.